bioMérieux : CA T4 et résultat annuel 2023 en ligne avec le css. Guidance de ROC contributif 2024 inférieur aux estimations courantes. Neutre vs Surperformance
>T4 +3,1% lfl. : - Marge Op. : 16,6% - Le CA T4 a atteint 1006 M€ (-2,2% et +3,1% lfl. / Css Visible Alpha: 1009 M€e - Css FactSet: 1005 M€e), soit 3674,7 M€ sur l’année (+2,4% et +6,6% lfl. / Css Visible Alpha: 3678 M€e - Css FactSet: 3674 M€e), avec un effet FX de -141 M€ ($, yuan, Peso argentin), et ROC av. GW ressort à 610 M€, -8,2 % et +2% lfl. (vs Css : 594 M€e-635 M€e) soit une MOP de 16,6% (vs 18,5% en 22). Le FCF 2023 ressort à 115 M€ (vs 195 M€ en 2022). A f...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.